ReviewJournal of clinical medicine2015
Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences.
Review in Journal of clinical medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease.Frontiers in pharmacology · 2022Pooled it
- Article
- Hypertension in Diabetes: Numbers or Outcomes?American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026Review
- Predictors of non-diabetic kidney disease in diabetics: A Saudi Arabian perspective.World journal of nephrology · 2025Article
- Urinary stress hormones and their metabolites as predictive biomarkers for CKD with diabetes.BMC nephrology · 2025Article
- Impact of optimal anti-proteinuric therapy on the prevention of diabetic kidney disease progression.Scientific reports · 2025Article
- Gene Expression Analysis in T2DM and Its Associated Microvascular Diabetic Complications: Focus on Risk Factor and RAAS Pathway.Molecular neurobiology · 2024Article
- Type 2 Diabetes and Chronic Kidney Disease: An Opportunity for Pharmacists to Improve Outcomes.Journal of clinical medicine · 2024Review
- Resistant Starch as a Dietary Intervention to Limit the Progression of Diabetic Kidney Disease.Nutrients · 2022Review
- Sodium-Glucose Cotransporter-2 Inhibitors Could Help Delay Renal Impairment in Patients with Type 2 Diabetes: A Real-World Clinical Setting.Journal of clinical medicine · 2022Article
- An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers.Current cardiology reviews · 2022Review
- Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy.Clinical diabetes : a publication of the American Diabetes Association · 2022Article
- Transforming the Care of Patients with Diabetic Kidney Disease.Clinical journal of the American Society of Nephrology : CJASN · 2021Review
- Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.Life sciences · 2021Review
- Diabetes and hypertension: Pivotal involvement of purinergic signaling.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Non-diabetic glomerular lesions in diabetic kidney disease: clinical predictors and outcome in an Eastern European cohort.International urology and nephrology · 2021Article
- Glomerular Filtration Dysfunction is Associated with Cardiac Adverse Remodeling in Menopausal Diabetic Chinese Women.Clinical interventions in aging · 2021Article
- Mitoquinone Protects Podocytes from Angiotensin II-Induced Mitochondrial Dysfunction and Injury via the Keap1-Nrf2 Signaling Pathway.Oxidative medicine and cellular longevity · 2021Article
- Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes.Biology · 2020Review
- Management of proteinuria: blockade of the renin-angiotensin-aldosterone system.Australian prescriber · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic Kidney Disease (DKD) is the leading cause of chronic kidney disease in developed countries and its prevalence has increased dramatically in the past few decades. These patients are at an increased risk for premature death, cardiovascular disease, and other severe illnesses that result in frequent hospitalizations and increased health-care utilization. Although much progress has been made in slowing the progression of diabetic nephropathy, renal dysfunction and the development of end-stage renal disease remain major concerns in diabetes. Dysregulation of the renin-angiotensin-aldosterone system (RAAS) results in progressive renal damage. RAAS blockade is the cornerstone of treatment of DKD, with proven efficacy in many arenas. The theoretically-attractive option of combining these medications that target different points in the pathway, potentially offering a more complete RAAS blockade, has also been tested in clinical trials, but long-term outcomes were disappointing. This review examines the "state of play" for RAAS blockade in DKD, dual blockade of various combinations, and a perspective on its benefits and potential risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.